--- title: "全球心臟生物標誌物診斷行業研究 2024-2029：心血管疾病高發和高靈敏度 POCT 推動變革性增長" type: "News" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/228677973.md" description: "《2024-2029 年全球心臟生物標誌物診斷行業》報告強調了該行業的增長，主要受到心血管疾病發病率上升和診斷技術進步的推動。主要參與者包括羅氏診斷和雅培快速診斷。由於高靈敏度檢測、複合生物標誌物和 POCT（牀邊檢測）採用率的提高，市場預計將顯著增長。亞太地區顯示出最快的增長潛力。報告涵蓋了實驗室檢測和 POCT 檢測方法，強調了在管理心臟疾病中早期檢測和全面診斷的重要性" datetime: "2025-02-18T10:43:36.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/228677973.md) - [en](https://longbridge.com/en/news/228677973.md) - [zh-HK](https://longbridge.com/zh-HK/news/228677973.md) --- # 全球心臟生物標誌物診斷行業研究 2024-2029：心血管疾病高發和高靈敏度 POCT 推動變革性增長 Dublin, Feb. 18, 2025 (GLOBE NEWSWIRE) -- The "Global Cardiac Biomarkers Diagnostics Industry, 2024-2029" report has been added to **ResearchAndMarkets.com's** offering. This research service provides an overview of the global cardiac biomarkers diagnostics industry and a 6-year global market revenue forecast from 2024 to 2029. The geographical scope covers four regions: North America, Europe, Asia-Pacific, and the Middle East, North Africa, and South Asia (MENASA) and Latin America. The market is moderately competitive driven by advances in biomarkers assays and technology alongside a continuous push for enhanced accuracy and high sensitivity of assays. Six players dominate the market: Roche Diagnostics, Abbott Rapid Diagnostics (formally Alere), Quidel Corporation, bioMerieux, Siemens Healthineers, and Danaher Corporation. There are limited players in lab analyzers, making this segment consolidated, while the assays space is more fragmented owing to the presence of numerous players. Labs are essential for precise testing and complex analysis, managing multi-marker panels (e.g., BNP, CK-MB, myoglobin, and troponin) to provide a comprehensive view of cardiac health. The global cardiac biomarkers diagnostics market is forecast to record robust growth with the increased prevalence of cardiovascular disease (CVD), multiplex biomarkers, advancements in diagnostic testing technology, higher POCT adoption rates, and an intensive focus on preventive healthcare. CVDs are a leading cause of mortality globally, highlighting the importance of early detection and intervention. The World Health Organization (WHO) estimates that in 2030, 23.3 million individuals will die from CVDs. Among these, acute myocardial infarction (AMI), acute coronary syndrome, and heart failure capture the greatest interest of researchers and healthcare professionals. Due to the high frequency - one-third of deaths - of this pathology globally, AMI is a key focus for WHO. Advancements in high-sensitivity cardiac troponin assays for AMI, such as Roche's Elecsys Troponin T hs make them vital in emergency departments throughout Europe and Asia, speeding up diagnosis and enhancing patient outcomes. Asia-Pacific is the fastest-growing region with high, untapped growth potential. Lab-based and POCT segments serve critical, distinct roles in the cardiac biomarkers diagnostics market. Lab tests provide high sensitivity and precision, which is essential for detailed risk assessment and ongoing observation. In contrast, POCT delivers rapid results at the patient's side, facilitating prompt decision-making in emergencies and remote locations. This balance of speed and accuracy ensures continued demand for both testing methods. Cardiac biomarkers are substances released into the bloodstream in response to heart damage or stress. They diagnose, assess risk, and manage conditions such as heart failure, myocardial infarction, and acute coronary syndrome. Testing locations discussed in the study include independent laboratories, physicians' offices, urgent care facilities, nursing facilities, hospitals, and emergency departments/rooms. The cardiac biomarkers diagnostics coverage includes vendor analysis encompassing instruments, consumables, reagents, kits, and assays. **The detailed examination of the cardiac biomarkers diagnostics market includes:** - Lab-based standardized tests that are approved by regulators and widely used by centralized labs. The biomarkers covered in this lab-based cardiac biomarkers segment include troponins, high-sensitivity troponins, BNP/NT-proBNP, hs-CRP, CK-MB biomarkers, and other biomarkers such as Neuregulin-1beta, ST2, Galectin, lipid profiles, and Copeptin. - POCT covers troponins, BNP, CK-MB, D-dimer, and myoglobin biomarkers for the global market. The study excludes laboratory-developed tests that are internally designed for specialized use without pre-market approvals. **Growth Opportunity Universe in the Global Cardiac Biomarkers Diagnostics Industry** - Growth Opportunity 1: High Sensitivity Assays (HSAs) - Growth Opportunity 2: Multi-marker Cardiac Panels for Comprehensive Diagnostics - Growth Opportunity 3: POCT Devices for Rural and Emerging Markets - Growth Opportunity 4: Convergence with Wearables and Apps for Early Detection and Real-time Monitoring **Key Topics Covered:** **Research Scope** - Scope of Analysis - Segmentation - History of Cardiac Biomarkers - Cardiac Biomarkers - Mechanism of Cardiac Biomarkers in Heart Failure **Growth Environment: Transformation in the Cardiac Biomarkers Diagnostics Industry** - Why Is It Increasingly Difficult to Grow? - The Strategic Imperative - The Impact of the Top 3 Strategic Imperatives on the Cardiac Biomarkers Diagnostics Industry **Ecosystem in the Global Cardiac Biomarkers Diagnostics Industry** - Competitive Environment - Key Competitors by Region **Growth Generator in the Cardiac Biomarkers Diagnostics Industry** - Growth Metrics - Growth Drivers - Growth Restraints - Emerging Biomarkers for the Detection of Cardiovascular Diseases - Cardiac Biomarkers Diagnostics Trends - Digital Health and Diagnostics Inter Convergence Model: Cardiac Diagnostics - Forecast Considerations - Revenue Forecast - Revenue Forecast Analysis - Revenue Forecast by Test Type - Revenue Forecast Analysis - Revenue Forecast by Region - Revenue Forecast Analysis by Region: NA - Revenue Forecast Analysis by Region: Europe - Revenue Forecast Analysis by Region: APAC - Revenue Forecast Analysis by Region: MENASA and Latin America - Pricing Trends and Forecast Analysis - Revenue Share - Revenue Share Analysis - Competitor Matrix - Global Cardiac Biomarkers Diagnostics Industry: Notable Activities **Growth Opportunity Analysis: Growth Generator in Lab-based Tests** - Growth Metrics: Lab-based Cardiac Biomarkers Diagnostics - Lab-based Cardiac Biomarkers Diagnostics Revenue Forecast - Lab-based Cardiac Biomarkers Diagnostics Revenue Forecast Analysis **Growth Opportunity Analysis: Growth Generator in POCT** - Growth Metrics: POCT Cardiac Biomarkers Diagnostics - POCT Cardiac Biomarkers Diagnostics Revenue Forecast - POCT Cardiac Biomarkers Diagnostics Revenue Forecast Analysis **Appendix & Next Steps** - Benefits and Impacts of Growth Opportunities - Next Steps For more information about this report visit https://www.researchandmarkets.com/r/orm699 **About ResearchAndMarkets.com** ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. ### 相關股票 - [688075.CN](https://longbridge.com/zh-HK/quote/688075.CN.md) ## 相關資訊與研究 - [邁威生物產品邁衞健獲準增加實體腫瘤骨轉移和多發性骨髓瘤適應症](https://longbridge.com/zh-HK/news/287136272.md) - [裕融估今年營收優預期 馬來西亞業務開始貢獻獲利](https://longbridge.com/zh-HK/news/287169918.md) - [大行報告丨花旗上調中芯國際評級至買入](https://longbridge.com/zh-HK/news/286705955.md) - [裕融法説會／東南亞轉投資有雙位數成長](https://longbridge.com/zh-HK/news/287192661.md) - [中信銀海外獲利佔比 35% 近年最高 週五董事會討論融保機製出資額](https://longbridge.com/zh-HK/news/286872710.md)